Drug Trial Radar · NCT05504317
A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Mar 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
May 28, 2020
Primary completion
Mar 2, 2021
Study completion Mar 2, 2021
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Aug 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib clinical study of multiple dose escalation of AK111 in subjects with moderate-to-severe plaque psoriasis
Conditions
- Psoriasis
Interventions
AK111Drug
Subjects will receive one of four escalated doses of AK111 (75mg/150mg/300mg/450mg) injection subcutaneously.
PlaceboDrug
Subjects will receive corresponding dose of placebo injection subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of SafetyTime frame: Baseline till Week 20
- PK evaluation: T1/2Time frame: Baseline till week 20
- PK evaluation: AUCTime frame: Baseline till week 20
- PK evaluation: CmaxTime frame: Baseline till week 20
- PK evaluation: TmaxTime frame: Baseline till week 20
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
AkesoBio Investigative Site 1001
Beijing, China
AkesoBio Investigative Site 1002
Bengbu, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.